Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential

Structure Therapeutics, Inc. Sponsored ADR (GPCR) has received a new Buy rating, initiated by Citi analyst, Samantha Semenkow.

Samantha Semenkow’s rating is based on Structure Therapeutics’ promising pipeline and potential in the obesity treatment market. The company is focused on developing oral small-molecule therapies, with its lead drug, aleniglipron, showing encouraging results in Phase 2b trials for obesity. The drug’s competitive weight loss data and favorable tolerability position it well in the market.
Furthermore, Structure Therapeutics has a diverse pipeline, including ACCG-2671, a first-in-class oral small-molecule amylin agonist. The anticipation of partnership interest and multiple stock-moving catalysts throughout 2025, along with the expected data from ongoing trials, supports the Buy rating. The potential for significant share price return further underscores the investment opportunity.

Semenkow covers the Healthcare sector, focusing on stocks such as Immunovant, Catalyst Pharma, and Larimar Therapeutics. According to TipRanks, Semenkow has an average return of -23.4% and a 22.73% success rate on recommended stocks.

In another report released on April 22, H.C. Wainwright also maintained a Buy rating on the stock with a $80.00 price target.